CA
NZ
UK
AU
IND
US
Two things happened inside two weeks that changed how Johnson & Johnson (NYSE:JNJ) is being framed. First, second-quarter results in mid-July came with raised full-year 2026 guidance: reported sales of $100.8bn to $101.4bn, up from $100.3bn to $101.3bn, with adjustedEarnings Per Sharelifted to $11.60–$11.75 …
Krystal Biotech (Nasdaq:KRYS) closed at $341.12 on Friday, down 7.01%, or $25.73, on volume of 488,157 shares. The company published no news that day. Its only July announcement was the routine 23 July notice that second-quarter results would be released on 3 August, and …
Gilead Sciences (Nasdaq:GILD) enters August with the densest regulatory calendar it has faced in years and a share price well below its 2026 peak. The FDA's target action date for bictegravir plus lenacapavir, a once-daily single-tablet regimen for adults already virologically suppressed, is, following …
Globus Medical (NYSE:GMED) closed at $78.79 at last closing, down 1.83% on the session, according to aggregated market data's price history. That leaves the shares roughly 22% below the $101.40 high of the past 52 weeks, even though the company has beaten and raised …
Guardant Health (Nasdaq:GH) closed at $161.99, up 6.33% on the day, after reporting second-quarter revenue of $335.0 million, 44% above the prior year, and lifting full-year guidance for the second time in 2026. Guidance rose to $1.34–$1.36 billion from $1.30–$1.32 billion, implying 36% to …
IDEXX Laboratories (Nasdaq:IDXX) closed at $559.07 on Friday, up 0.05% on the day, a move small enough to round to nothing, three sessions before the veterinary diagnostics company reports second-quarter results. The company confirmed on 1 July that the release arrives before the market …
Illumina (Nasdaq:ILMN) used its July 30 second-quarter report to do something it has rarely managed this decade: raise the year. Revenue of $1.16 billion rose 9.5% against Q2 2025, and 8.1% excluding currency, acquisitions and China. Non-GAAP diluted earnings of $1.31 a share came …
Incyte (Nasdaq:INCY) reported second-quarter results on 28 July. Total revenues reached $1.67 billion, up 38% year over year, and management lifted full-year net product sales guidance to $5.13–$5.26 billion from $4.77–$4.94 billion. "Our second quarter was marked by broad-based sales growth, continued pipeline progress …
Elanco Animal Health (NYSE:ELAN) closed at $26.37, down nine cents, or 0.34%, on volume of about 5.2 million shares. That is a shrug of a session, and an unusually calm one, given what happens next. The company reports second-quarter results on Wednesday, 5 August, …
Lilly (NYSE:LLY) reports second-quarter 2026 results on August 5 and hosts a conference call at 10 a.m. Eastern. Investors already know roughly what the injectables will do. What they do not know is whether the company's oral GLP-1, Foundayo (orforglipron), is a slow starter …
Please wait processing your request...